Every 8-K that Genelux Corporation (GNLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GNLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNLX filings page.
Genelux Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. As of the April 17, 2026 record date, 44,842,243 common shares were outstanding and entitled to vote, and 28,263,200 shares were represented in person, virtually or by proxy, about 63.03% of those eligible.
Stockholders elected Class I director John Smither to serve until the 2029 Annual Meeting, with 8,696,891 votes for, 3,393,408 withheld, and 16,172,901 broker non-votes. They also ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,092,768 votes for, 105,158 against, 65,274 abstentions, and no broker non-votes.
Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC that allows it to sell up to $100,000,000 of common stock through an at-the-market offering program. Shares will be issued from an existing shelf registration and sold on Nasdaq or in other permitted transactions.
Genelux can choose when and whether to sell, and either party may terminate the arrangement by written notice. TD Securities (TD Cowen) will receive up to 3.0% of gross proceeds and certain expenses, while net proceeds are earmarked for general corporate purposes, including research, clinical trials, capital spending, and working capital.
Genelux Corporation filed a current report outlining an update to its corporate presentation with new business and strategic information. The refreshed presentation, dated February 2026, may be used by management in future meetings and is available in the Investors section of the company’s website.
The presentation is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed for liability purposes under the Exchange Act or incorporated into other securities filings unless specifically referenced.
Genelux Corporation is conducting an underwritten public offering of 6,666,667 shares of common stock at $3.00 per share, for expected gross proceeds of about $20.0 million before fees and expenses. All shares are being sold by the company, so the transaction raises new capital for Genelux rather than existing shareholders. The offering is being made under an effective Form S-3 shelf registration statement, with closing expected on January 9, 2026, subject to customary conditions.
Genelux Corporation reduced the exercise prices of certain employee stock options to $3.33 per share, matching the closing price of its common stock on September 1, 2025. The change applies to approximately 2,715,583 option shares under its 2009, 2019 and 2022 equity incentive plans that previously had exercise prices between $6.00 and $22.40 per share. Executive officers affected include President and CEO Thomas Zindrick with 1,355,940 option shares repriced, Senior VP Clinical Development Tony Yu with 272,652, Chief Technical Officer Joseph Cappello with 174,999, and Head of Regulatory Ralph Smalling with 8,333. Options held by non-employee directors and those granted under the 2023 Inducement Plan were not changed, and all modified options keep their original vesting schedules and expiration dates.
The Board concluded that this repricing, permitted under the plans, supports employee retention and incentives while preserving cash and avoiding stock dilution from large new equity grants. At the 2025 Annual Meeting of Stockholders, held August 27, 2025, stockholders elected Class III directors Thomas Zindrick and James Tyree, with 13,677,099 and 12,485,839 votes for, respectively. Stockholders also ratified Weinberg & Company, P.A. as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 25,664,455 votes for, 609,586 against and 430,107 abstentions. Meeting attendance was 26,704,149 shares, representing 70.72% of shares outstanding as of the June 30, 2025 record date.